Tacsant 1mg Capsule

Tacsant 1mg Capsule is a medicine containing tacrolimus. It is an immunosuppressive drug used mainly to prevent organ rejection in patients who have undergone kidney, liver or heart transplant. It suppresses the immune system so it does not attack the transplanted organ.

Uses of Tacsant 1mg Capsule:

Prevention of organ rejection in transplant patients (kidney, liver, or heart transplants)

How does the Tacsant 1mg Capsule work?

Tacrolimus blocks an enzyme called calcineurin that is required to activate T-cells of the immune system. Tacrolimus blocks this route to reduce the immune response and prevent rejection of the organ.

How to Use & Dosage

Tacrolimus is available in several forms and should be taken as directed, with immediate-release capsules taken twice daily and extended-release forms taken once daily on an empty stomach. Take tacrolimus at the same time each day as directed by your doctor.

Do not split, chew or crush extended-release capsules; instead, swallow capsules whole with water. Do not open or crush the immediate-release capsules.

Possible Side Effects:

• Tremors
• Rash
• Headache
• Nausea
• Vomiting
• Dizziness
• Fatigue
• Diarrhea
• High blood pressure
• Kidney dysfunction
• High blood sugar levels

Safety Advise:

Kidney

Tacrolimus can cause nephrotoxicity thus kidney function should be monitored regularly. Talk to your health care provider.

Liver

Tacrolimus can cause liver impairment and liver function should be monitored regularly. Talk with your healthcare provider.

Pregnancy

Tacsant should be used in pregnancy only if clearly needed. Please consult your healthcare provider.

Breast Feeding

Using Tacsant 1mg Capsule while nursing is most likely unsafe. Please consult your physician.

Alcohol

Alcohol should not be taken with Tacsant 1mg Capsule. Talk to your doctor.

Storage Instructions:

Keep Tacsant capsules at temperature between 15°C and 30°C (59°F and 86°F). Store capsules in original packaging to protect from light and moisture. Keep away from children.

References

1. Tripathi KD. Immunosuppressive Drugs. In: Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019.
2. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Immunosuppressants, Tolerogens, and Immunostimulants. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.
3. Astellas Pharma US, Inc. Prograf (tacrolimus) capsules, injection: full prescribing information, including Boxed Warning. Northbrook, IL: Astellas Pharma US, Inc.; 2020.
4. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant International. 2000;13(5):313-326.
5. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623-628.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.